Abstract
Objectives: Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein that may be a useful prognostic biomarker in nasopharyngeal cancer (NPC). The purpose of this systematic review and meta-analysis was to investigate the relationship between PD-L1 expression and survival in NPC. Methods: PubMed, Cochrane, Embase, Scopus, and Web of Science were searched from inception to present. A predefined inclusion and exclusion criteria were used to select articles. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled for overall survival (OS), disease-free survival (DFS), and disease metastasis-free survival (DMFS). Results: Eleven studies published from 2014 to 2018 were included, with 1,356 total participants. PD-L1 expression was not associated with OS (HR = 1.10, 95% CI: 0.79-1.55), DFS (HR = 1.66, 95% CI: 0.68-4.03), or DMFS (HR = 1.18, 95% CI: 0.44-3.20). Conclusions: The prognostic role of PD-L1 in NPC remains unsubstantiated. Future research is needed. Laryngoscope, 130:2598–2606, 2020.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2598-2606 |
| Number of pages | 9 |
| Journal | Laryngoscope |
| Volume | 130 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 1 2020 |
| Externally published | Yes |
Keywords
- Head and neck neoplasms
- immune checkpoint
- nasopharyngeal carcinoma
- prognostic biomarker
- programmed death-ligand 1
ASJC Scopus subject areas
- Otorhinolaryngology
Fingerprint
Dive into the research topics of 'The Prognostic Role of Programmed Death-Ligand 1 in Nasopharyngeal Carcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS